A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer

Inclusion Criteria: * Male and Female patients \>18 years with a histologically/cytologically confirmed diagnosis of locally advanced or metastatic cancer ,for whom no anti-tumor therapy of proven benefit is available at study enrollment. * ECOG 0-2. * Life expectancy of at least 3 months. * Measurable or non-measurable disease according to RECIST v1.1 criteria. * Patients should have at least one measurable lesion or disease which is non-measurable but can be clearly be evaluated for response. * Adequate bone marrow function as evidenced by an absolute neutrophil count :1500 cell/ul. * Hb greater than 9.5 g/dL and a platelet count greater than 100,000/ uL. * Renal function \>50ml/min with estimated creatinine clearance (eCcr) using the Cockcroft-Gault formula or serum creatinine\<1.5 mg/dL. * Adequate hepatic function as evidenced by serum total bilirubin \<3.0 mg/dL, and AST and ALT less than 5 times the upper limit of normal(ULN). * Signed informed consent. Exclusion Criteria: * Patients with lymphoma, hematological cancer or glioblastoma multiforme. * Active infection, or a fever \>38.5C within three days prior to the first day of study drug dosing. * Current or past history evidence of disease (hemolytic diathesis, hemochromatosis) that could be exacerbated by administering liposomal curcumin. * Currently on coumadin or coumadin derivatives(oral anticoagulants), or any medications classified as cytochrome p450 inhibitors or inducers. * Last systemic therapy less than three(3) weeks before (six weeks if treatment was with BCNU or CCNU). * Unresolved toxicities from prior systemic anti-cancer therapy except symptomatic motor or sensory neuro-toxicities NCI-CTC Grade \<2. * Clinically significant ECG aberrations according to the discretion of the investigator. * Left ventricular ejection fraction (LVEF) \<50%.